Status:
RECRUITING
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
Lead Sponsor:
Boston Scientific Corporation
Conditions:
Parkinson Disease
Dystonia
Eligibility:
All Genders
Brief Summary
The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functi...
Detailed Description
The objective of this study is to compile real-world outcomes of Boston Scientific Corporation commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for u...
Eligibility Criteria
Inclusion
- Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)
- Signed a valid, IRB/EC/REB-approved informed consent form
Exclusion
- Meets any contraindications per locally applicable Directions for Use (DFU)
- Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments
Key Trial Info
Start Date :
January 29 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2035
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06553625
Start Date
January 29 2024
End Date
December 1 2035
Last Update
December 8 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Uniklinik Köln
Cologne, Germany
2
Universitaetsklinikum Dusseldorf
Düsseldorf, Germany
3
Universitaetsklinikum Wuerzburg
Würzburg, Germany
4
St. Georges Hospital
London, United Kingdom